By Ritsuko Kawa – Wired –
Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells. These will be the world’s first practical application of iPS cell-derived products.
